New pulmonary therapies for cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 6, 2007, Pages 541-546

  Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Chloride secretion; Cystic fibrosis; Cystic fibrosis transmembrane regulator pharmacotherapy; Gene therapy; Osmotic therapy

Indexed keywords

ADENOVIRUS VECTOR; AMILORIDE; AMINOGLYCOSIDE; ARGININE; ARYLBUTYRIC ACID DERIVATIVE; CHLORIDE CHANNEL BLOCKING AGENT; CURCUMIN; DENUFOSOL; DURAMYCIN; GENTAMICIN; MANNITOL; OSMOTIC AGENT; PLACEBO; SIMVASTATIN; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 770;

CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; HUMAN; LUNG DISEASE; NONVIRAL GENE THERAPY; OSMOSIS; REVIEW; SODIUM ABSORPTION;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG DISEASES; PEPTIDE FRAGMENTS; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME;

EID: 34848821636     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282efbc56     Document Type: Review

References (49)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-1073.
2. Griesebach U, Geddes D, Alton E. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006; 13:1061-1067. Summarizes current gene strategies.
3. Leung K, Louca E, Munson K, et al. Calculating expected lung deposition of aerosolized administration of AAV vector in human clinical studies. J Gene Med 2007; 9:10-21.
4. Moss R, Rodman D, Spencer L, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125:509-521.
5. Kerem E. Mutation specific therapy in CF. Paediatr Respir Rev 2006; 7:S166-S169.
6. Welsh M, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The molecular and metabolic basis of inherited disease. New York: McGraw-Hill; 2001. pp. 5121-5188.
7. Clancy J, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:1683-1692.
8. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349:1433-1441.
9. Welch E, Barton E, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 441:87-91.
10. Clancy J, Rowe S, Bebok Z, et al. No detectable improvements in CFTR by nasal aminoglycosides in CF patients with stop mutations. Am J Respir Cell Mol Biol 2007; 37:57-66.
11. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117:683-692. Gives a functional explanation for the variability in response seen in patients following readthrough therapy.
12. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007; 5:5.
13. Cheng S, Gregory R, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63:827-834.
14. Vij N, Fang S, Zeitlin P. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 2006; 281:17369-17378.
15. Zeitlin P, Diener-West M, Rubenstein R, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6:119-126.
16. Egan M, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304:600-602.
17. Dragomir A, Bjorstad J, Hjelte L, Roomans G. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2006; 322:447-451.
18. Song Y, Sonawane N, Salinas D, et al. Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 2004; 279:40629-40633.
19. Wang W, Bernard K, Li G, Kirk K. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 2006; 282:4533-4544.
20. Pedemonte N, Lukacs G, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2001; 115:2564-2571.
21. Van Goor F, Straley K, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Cell Physiol 2006; 290:L1117-L1130.
22. Tsuji S, Kikuchi S, Shinpo K, et al. Proteasome inhibition induces selective motor neuron death in organotypic slice cultures. J Neurosci Res 2005; 82:443-451.
23. Guilbault C, Saeed Z, Downey G, Radzioch D. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 2007; 36:1-7.
24. Tarran R, Button B, Picher M, et al. Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem 2005; 280:35751-35759.
25. Knowles M, Clarke L, Boucher R. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 3252:533-538.
26. Bennett W, Zeman K, Foy C, et al. Effect of aerosolized uridine 5′-triphosphate on mucociliary clearance in mild chronic bronchitis. Am J Respir Crit Care Med 2001; 164:302-306.
27. Deterding R, Retsch-Bogart G, Milgram L, et al. Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005; 39:339-348.
28. Deterding R, Lavange L, Engels J, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007; 19 April [Epub ahead of print]. Clinical study on a new approach to circumvent the CFTR defect.
29. Zeitlin P, Boyle M, Guggino W. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2005; 25:143-149.
30. Grasemann H, Stehling F, Brunar H, et al. Inhalation of moli1901 in patients with cystic fibrosis. Chest 2007; 131:1461-1466. Clinical study showing the efficacy on lung function of a non-CFTR-mediated pharmacotherapy.
31. Reddy M, Light MJ, Quinton P. Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function. Nature 1999; 402:301-304.
32. Mall M, Grubb B, Harkema J, et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004; 10:487-493.
33. Burrows E, Southern K, Noone P. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2006; (3).
34. Donaldson S, Bennett W, Zeman K, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241-250.
35. Levin M, Sullivan S, Nielson D, et al. Hypertonic saline therapy in cystic fibrosis: evidence against the proposed mechanism involving aquaporins. J Biol Chem 2006; 281:25803-25812.
36. Hirsh A, Molino B, Zhang J, et al. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem 2006; 49:4098-4115.
37. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006; 354:291-293.
38. Robinson M, Hemming A, Regnis J, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52:900-903.
39. Elkins M, Robinson M, Rose B, et al., National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229-240.
40. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007; 42:471-476.
41. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14:678-685.
42. Grasemann H, Ratjen F. Cystic fibrosis lung disease: the role of nitric oxide. Pediatr Pulmonol 1999; 28:442-448.
43. Wood S, Firoved A, Ornatowski W, et al. Nitrosative stress inhibits production of the virulence factor alginate in mucoid Pseudomonas aeruginosa. Free Radic Res 2007; 41:208-215.
44. Yoon S, Coakley R, Lau G, et al. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest 2006; 116:436-446.
45. Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:208-212. Augmentation of nitric oxide production improved lung function and oxygen saturation in cystic fibrosis patients.
46. Hopkins N, Gunning Y, O'Croinin D, et al. Anti-inflammatory effect of augmented nitric oxide production in chronic lung infection. J Pathol 2006; 209:198-205.
47. Zaman K, Carraro S, Doherty J, et al. S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis. Mol Pharmacol 2006; 70:1435-1442.
48. Alton E, Davies J, Geddes D. Biomarkers for cystic fibrosis: are we progressing? Am J Respir Crit Care Med 2007; 175:750-751.
49. Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006; 41:656-665.